Implantica Receives FDA Approval for RefluxStop Device
Implantica AG announced it has received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for its RefluxStop device. The approval grants the company access to the U.S. market.
Liechtenstein-based Implantica AG, a medical technology company, has secured Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for its RefluxStop device. This approval signifies a critical step for the company as it prepares to enter the significant U.S. market for medical devices.
RefluxStop is designed to treat gastroesophageal reflux disease (GERD) by stimulating the vagus nerve. Clinical studies cited by the company indicate that the device offers an effective treatment option without the need for surgical intervention or permanent alterations to the digestive system. The FDA's decision follows a review of clinical trial data assessing the safety and efficacy of the device.
Implantica CEO Peter Näslund stated that the FDA approval represents a major milestone for the company's growth strategy. "We are excited to bring a new treatment option to millions of Americans suffering from GERD," Näslund said. The U.S. market entry is expected to accelerate Implantica's overall global expansion.
The FDA clearance allows Implantica to begin commercializing RefluxStop within the United States. While a specific launch timeline has not yet been detailed, the company anticipates making the device available to patients in the near future. This move positions Implantica to tap into one of the world's largest healthcare markets.